Serabelisib (INK-1117,MLN-1117,TAK-117)
97%
- Product Code: 57240
CAS:
1268454-23-4
| Molecular Weight: | 363.37 g./mol | Molecular Formula: | C₁₉H₁₇N₅O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Serabelisib is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as a selective inhibitor of the PI3K alpha isoform, which plays a critical role in cell growth and survival. By blocking this pathway, it helps to inhibit the proliferation of cancer cells, particularly in tumors that exhibit PI3K pathway activation.
This compound has been investigated in clinical trials for its potential in treating various solid tumors, including breast, endometrial, and ovarian cancers. It is often studied in combination with other therapeutic agents to enhance its efficacy and overcome resistance mechanisms in cancer cells.
Serabelisib’s ability to specifically target the PI3K alpha isoform makes it a promising candidate for precision medicine, offering a more tailored approach to cancer treatment with potentially fewer side effects compared to broader-spectrum therapies. Research continues to explore its full potential in improving patient outcomes in specific cancer subtypes.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $428.53 |
+
-
|
Serabelisib (INK-1117,MLN-1117,TAK-117)
Serabelisib is primarily used in the field of oncology as a targeted therapy for cancer treatment. It functions as a selective inhibitor of the PI3K alpha isoform, which plays a critical role in cell growth and survival. By blocking this pathway, it helps to inhibit the proliferation of cancer cells, particularly in tumors that exhibit PI3K pathway activation.
This compound has been investigated in clinical trials for its potential in treating various solid tumors, including breast, endometrial, and ovarian cancers. It is often studied in combination with other therapeutic agents to enhance its efficacy and overcome resistance mechanisms in cancer cells.
Serabelisib’s ability to specifically target the PI3K alpha isoform makes it a promising candidate for precision medicine, offering a more tailored approach to cancer treatment with potentially fewer side effects compared to broader-spectrum therapies. Research continues to explore its full potential in improving patient outcomes in specific cancer subtypes.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :